Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.08%
SPX
-0.22%
IXIC
-0.51%
FTSE
-0.20%
N225
-0.22%
AXJO
-0.21%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks

INCY is now overvalued and could go down -34%

Mar 01, 2025, 1:00 PM
-16.69%
What does INCY do
Yte is a Wilmington, Delaware-based biopharmaceutical company with 2,524 employees, focusing on hematology/oncology and inflammation/autoimmunity therapeutic areas. Its product portfolio includes JAKAFI, MONJUVI, and PEMAZYRE, among others.
Based on our analysis, yte has received an overvalued rating of 1 out of 5 stars from Cashu. This assessment is primarily driven by its significantly high price-to-earnings (PE) ratio of 431.88, compared to the sector average of 14.78. A PE ratio measures a company's current share price relative to its earnings per share, indicating how much investors are willing to pay for each dollar of earnings. In yte's case, the excessive PE ratio suggests that investors may be overpaying relative to the company’s earnings potential. Additionally, yte's price-to-book (PB) ratio stands at 3.86, while the sector average is 2.69. The PB ratio compares a company's market value to its book value, helping to assess whether a stock is undervalued or overvalued. A higher PB ratio can indicate that the market is pricing yte at a premium, which may not be justified by its asset base. Furthermore, while yte exhibits a positive net profit margin of 0.77, it is important to note that this figure is in stark contrast to the sector's average of -138.53. Although a positive margin reflects profitability, the extreme sector loss indicates that yte's profitability may not be sustainable. These financial ratios collectively highlight concerns regarding yte’s valuation compared to its industry peers. Investors should consider these metrics when evaluating the stock's current price. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.